Clinical and pharmacokinetic phase II study of one hour infusion of kahalalide F administered every week to patients with Non Small Cell Lung Cancer Stage IIIB with pleural effusion and stage IV, after first line chemotherapy

开始日期2004-05-13

申办/合作机构

Pharma Mar SA

100 项与 Kahalalide F 相关的临床结果

登录后查看更多信息

100 项与 Kahalalide F 相关的转化医学

登录后查看更多信息

100 项与 Kahalalide F 相关的专利（医药）

登录后查看更多信息

项与 Kahalalide F 相关的文献（医药）

2025-09-26·JOURNAL OF NATURAL PRODUCTS

Structure Determination and Biosynthesis of Dapalides A–C, Glycosylated Kahalalide F Analogues from the Marine Cyanobacterium Dapis sp

Article

作者: Donia, Mohamed S. ; Luesch, Hendrik ; Liu, Jie ; Bruner, Steven D. ; Ellis, Emma K. ; Ióca, Laura P. ; Ding, Yousong ; Paul, Valerie J. ; Chen, Manyun

Kahalalides were originally isolated from the marine mollusk Elysia rufescens and its green algal diet Bryopsis sp., but the true producer was revealed as the obligate bacterial symbiont Candidatus Endobryopsis kahalalidefaciens, residing within Bryopsis sp. The most notable is kahalalide F, a broad-spectrum antitumor depsipeptide that entered the clinic but failed from lack of efficacy. We have isolated three new glycosylated analogues of kahalalide F, termed dapalides A-C (1-3), from a marine cyanobacterium, Dapis sp., collected from Guam. The planar structures were determined by extensive NMR coupled with mass spectrometry. Acid hydrolysis of 1 using amino acid analysis revealed the absolute configuration of singlet and a mixture of duplicate amino acids. Metagenomic analysis unveiled a biosynthetic gene cluster (BGC) with a nonribosomal peptide synthetase (NRPS) system and downstream glycosylation enzymes, which assisted the configurational assignment through epimerization domain analysis. The discovered BGC, termed dap, was assigned to a high-quality metagenome-assembled genome of the Dapis sp. Dapalide A (1) was subjected to phenotypic bioassays and exhibited weak anticancer cytotoxicity. This discovery expands the chemical diversity of the kahalalide F family, suggests their broad ecological role across diverse organisms, and presents an intriguing case of natural product biosynthesis evolution.

2025-09-03·Journal of the American Chemical Society

Cyanobacteria Join the Kahalalide Conversation: Genome and Metabolite Evidence for Structurally Related Peptides

Article

作者: Rob Knight ; M. Omar Din ; Jehad Almaliti ; Nicole E. Avalon ; William H. Gerwick ; Evgenia Glukhov ; Caitriona Brennan ; Marine Cuau ; Lena Gerwick ; Byeol Ryu

Kahalalide F is a cyclic depsipeptide with notable anticancer properties, initially discovered from the green alga Bryopsis sp. and its molluscan predator Elysia rufescens. Recent studies have pinpointed a bacterial endosymbiont of the green alga, Candidatus Endobryopsis kahalalidefaciens, as the true producer of kahalalide F. In the present work, we characterize a closely related kahalalide F analog, kahalalide Z₅, from the marine cyanobacterium Limnoraphis sp. collected in the Las Perlas Islands, Panama, and propose the structures of several related compounds by detailed MS analysis. To uncover novel metabolites and prioritize them for targeted isolation from this organism, we employed a robust metabolomics strategy combining LC-MS/MS with SMART NMR and DeepSAT, artificial intelligence platforms trained to infer chemical structures from ¹H-¹³C HSQC NMR data. This integrated approach annotated a compound with structural similarities to kahalalide F, which we subsequently characterized using a suite of spectroscopic techniques and chemical degradation studies. Whole-genome sequencing of the producing strain further revealed a NRPS biosynthetic gene cluster that aligns with the structural features of kahalalide Z₅. This study identifies the marine cyanobacterium Limnoraphis sp. as an independent source of kahalalide F-like molecules. This work broadens the phylogenetic spectrum of organisms capable of producing these bioactive compounds, reveals marine cyanobacteria as producers of an increased repertoire of unique natural products, and illustrates the potential of AI-enhanced metabolomic and genomic analyses to streamline the discovery and characterization of complex biomedically relevant natural products.

2017-09-01·Peptides3区 · 医学

Structural diversity of marine cyclic peptides and their molecular mechanisms for anticancer, antibacterial, antifungal, and other clinical applications

3区 · 医学

Review

作者: Hong, Soon-Cheol ; Lee, Yeji ; Phat, Chanvorleak

Many cyclic peptides and analogues derived from marine sources are known to possess biological properties, including anticancer, antitumor, antibacterial, antifungal, antiparasitic, anti-inflammation, anti-proliferative, anti-hypertensive, cytotoxic, and antibiotic properties. These compounds demonstrate different activities and modes of action according to their structure such as cyclic oligopeptide, cyclic lipopeptide, cyclic glycopeptide and cyclic depsipeptide. The recent advances in application of the above-mentioned cyclic peptides were reported in dolastatins, soblidotin, didemnin B, aplidine, salinosporamide A, kahalalide F and bryostatin 1 and they are currently in clinical trials. These cyclic peptides are possible novel drugs discovered and developed from marine origin. Literature data concerning the potential properties of marine cyclic peptides were reviewed here, and the structural diversity and biological activities of marine cyclic peptides are discussed in relation to the molecular mechanisms of these marine cyclic peptides.

项与 Kahalalide F 相关的新闻（医药）

2025-10-27

·肽库

海洋活性多肽的研究进展

摘要：根据海洋活性多肽是近年来新药研究热点的现状 , 本文对天然存在的海洋活性多肽和海洋蛋白酶解活性肽的研究进展进行了综述。为进一步开展海洋活性多肽的研究提供参考。关键词：海洋活性多肽海洋生物海洋蛋白酶解物海洋天然生物活性物质是现代生物学研究的热点, 而天然海洋活性多肽是海洋活性物质研究的重要组成部分。由于海洋生物的生活环境与陆地生物迥异, 海洋生物具有多样性、复杂性和特殊性, 从而使源于其中的海洋天然产物与陆地天然产物不同, 这为寻找新的天然活性物质提供了丰富的物质来源。生物活性多肽是具有特殊生理活性的肽类, 按其来源可分为天然存在的活性肽、蛋白酶解活性肽以及化学合成的活性肽。自1902年, 伦敦大学医学院的Bayliss 和Starling第一次发现活性多肽物质——促胰液素 [1] (secretin) 以来, 人们对多肽的研究逐渐深入, 并且发现了数万种的生物活性多肽, 其中有近百种多肽作为药物进行生产。为人类抵御疾病作出了重大贡献。从目前研究的情况来看, 海洋天然活性多肽的研究主要集中在海绵、芋螺、海葵、海藻等少数几种海洋生物中。作用也十分明确:抗肿瘤、抗病毒、免疫调节等。尽管大量的活性多肽已经从海洋生物中分离得到, 但其中仅有少部分可作为药品进行开发进入市场, 相当多的新化合物作为先导化合物, 为新药的研究提供线索;还有一些海洋活性多肽在生物体内的含量很少, 所以在其生理活性和结构确定后, 采用全合成和固相合成的技术实现其产业化生产。本文就近年来海洋活性多肽的研究进展作一综述。1 天然存在的海洋活性多肽近年来, 许多科学家致力于从深海细菌、真菌、微藻以及海洋软体动物中分离活性肽, 并且取得了很大进展。这些活性肽结构复杂多样, 参与生物体的重要生命活动, 具有重要的基础研究及临床应用价值, 是一类非常重要的新药来源。 1.1 抗菌肽有些生物体在受到外界环境刺激时产生大量具有抗菌活性的阳离子多肽, 从而使其具有天然免疫力。目前, 已有百余种抗菌肽被分离, 有些抗菌肽不仅具有很强的杀菌能力, 还能杀死肿瘤细胞。这些海洋多肽类化合物的发现为寻找新的抗生素提供了线索。 1996年, Hamann, M.T. [2-3] 等报道了从Sacoglossan Mullusk Elysia rufescens 中分离得到6种环状缩醛肽Kahalalide A-F, 其中Kahalalide A和F均有不同程度的抗结核杆菌的活性。进一步的研究表明, Kahalalide F (图1) 还表现极强的细胞毒性, 已经用于肝癌的治疗。图1 Kahalalide F的化学结构西班牙马德里的马尔生物制药公司 (PharmaMar, www.pharmamar.com ) 药厂在2003年5月正式宣布, 使用 Kahalalide F 治疗肝癌末期病患的第一阶段临床实验成果良好, 并将进入第二阶段。Kahalalide F 和其他所有抗癌剂最大的不同点在于, 它可以改变溶酶薄膜的作用 (属于细胞内消化系统) 。研究指出Kahalalide F在活体内可以导致癌细胞死亡, 在活体外则可区别癌细胞与正常细胞。至于杀死细胞的作用, 并不是透过信使核糖核酸 (mRNA) 或蛋白质结合, 也不是透过蛋白酵素的活动 [4] 。与Kahalalide F不同, Kahalalide A [5] (图2) 则未表现出明显的细胞毒性, 但是该化合物具有极强的抗结核杆菌的活性, 在浓度为12μg·mL-1时, 对结核杆菌M.tuberculosis (H37Rv) 的抑制率为83%, 是迄今为止发现的第3个具有抗结核杆菌的活性的海洋活性多肽, 值得进一步研究。图2 Kahalalide A的化学结构 1997年, Gerard, J. [5-6] 等报道了2种环状缩醛肽:Massetolide A和Viscosin, 二者都有很强的抗结核杆菌的活性。前者是从海洋微藻中分离的假单胞杆菌属菌株中提取得到的, 最小抑菌浓度MIC为2.5～5μg·mL-1, 后者是从1种管状蠕虫中分离得到, 最小抑菌浓度MIC为5～10μg·mL-1。图3 Massetolide A 和 Viscosin 的化学结构 2001年, Todd Barsby [7] 等从新几内亚海洋微生物枯草杆菌属的菌株中分离得到1种多肽类的抗生素Bogorol A, 该化合物能够对万古霉素耐药肠道球菌 (VRE) 和青霉素耐药金黄色葡萄球菌 (MRSE) 产生抵抗作用。图4 Bogorol A 的化学结构 1.2 抗肿瘤多肽许多存在于海洋生物体内的化合物具有显著的细胞活性, 为寻找抗肿瘤药物开辟了新途径。1987年, Pettit等首次从海兔 (Dolabella auricularia) 体内分离得到由4个氨基酸组成的线性小肽Dolastatin-10 [8-9] , 该化合物通过抑制微管聚合, 对人乳腺癌、非小细胞性肺癌有显著疗效, 具有良好的前景。目前, 美国国家癌症研究所 (NCI) 与基诺药厂 (Knoll) 合作, 该药正进入临床I期研究阶段 [10] 。近几年, Dolastatin-10的结构类似物Dolastatin H和Isodolastatin H相继被发现, 并且也显示出较强的抗肿瘤活性 [11] 。图5 Dolastatin-10 的化学结构图6 Dolastatin H 和 Isodolastatin 的化学结构 1997年, Isabelle Bonnard [12] 等从海洋丝状藻青菌 (Lyngbya majuscula) 中分离得到一系列具有细胞毒性和抗菌活性的环状脂肽, 其中最主要的2种化合物Laxaphycins A和B都具有非同一般的抗真菌和细胞毒性的生物协同作用, 药理实验表明, Laxaphycins A单独用药对细胞株的作用不大, 几乎无活性, 而Laxaphycins A能够潜在地提高Laxaphycins B的活性, 加入1μmol/L的Laxaphycins A, Laxaphycins B对人体淋巴母细胞的IC50值降低3倍。表1列举了目前制药公司、癌症研究所及多所大学, 正在研究的多种从海洋生物提取的抗癌化学成分, 其中一些很有希望成为药物。 1.3 抗病毒多肽 1999年, Paul W, Ford [22] 等从新几内亚海域采集的海绵 (Theonella mirabilis and Theonella swinhoei) 分离得到4种新化合物Papuamides A, B, C, D, 均为环状缩醛肽, 并且是首次发现分子结构中含有3-羟基亮氨酸和同型脯氨酸残基的海洋活性多肽。Papuamides A, B能够抑制体内由HIV-ⅠRF引起的T-淋巴细胞感染, 在体外的有效浓度EC50为3.6ng.mL-1, Papuamides A对癌细胞也具有细胞毒性, 其IC50为75ng.mL-1。 2001年, Mohammad A. Rashid. [23] 等从印度尼西亚海绵 (Sidonops microspinosa) 中分离得到一种新型的环状缩醛肽Microspisamide, 由13个氨基酸残基组成, 其中含有一个β-OH-BrPhe残基, 这是以前所发现的海洋多肽中从未见过的。该化合物能够抑制由HIV-Ⅰ感染引起的细胞病变。图7 Papuamides A, B 的化学结构图8 Microspisamide的化学结构 1.4 肽类毒素海洋生物中存在种类众多的肽类毒素, 这些毒素性质独特, 在生物医学、分子生物学的研究和应用方面有广阔的前景。目前研究较多的有芋螺毒素、海葵毒素, 其它的海洋生物毒素如水母毒素、章鱼毒素、海胆毒素、海蛇毒素、海兔毒素、微囊藻素等报道的较少。芋螺毒素 (Conotoxin CTX) [24] 是一类有10～30余个氨基酸残基组成的小肽, 含有2对或3对二硫键, 是迄今发现的最小核酸编码的动物神经肽毒素。芋螺毒素结合在神经和肌肉的受体上, 具有高亲和力和高度专一的特点, 是神经科学十分有效的探针。临床上用作特异诊断试剂, 作为镇痛药具有疗效确切、不成瘾的特点。多种芋螺毒素已申请国家专利。1998年, England等从地纹芋螺 (Conus geographus) 中分离得到δ-CTX GV Ⅲ A, 它是富含Gly和Thr的41肽, 是迄今发现的芋螺毒素中分子最大的一个。进一步的研究表明第34位为极为罕见的L-6-Br-色氨酸, 是该毒素的功能决定因子。海葵毒素 (Anthoplerin toxin AP) [25] 也是研究的热点, 是一类分子量范围为3 000～6 000, 由2～3个二硫键交联着的单链碱性分子, 其一级结构可分为3种类型。但以后分离出来的calitoxin, BTTX Ⅱ和AEX Ⅱ, AEX Ⅲ与经典的3种类型有较大不同, 代表着新颖结构类型的海葵毒素多肽。海葵毒素主要特异结合在心脏Na+通道上, 是一类非常有价值的钠通道研究工具药。 1.5 肽类激素 1997年, Gary P. Richards [26] 等黑海鱼 (Centropristis striata) 骨骼肌纤维中分离得到一种鱼类激肽释放酶原Prokallikrein。激肽释放酶kallikreins在鱼体内有多种功能, 首先它能够促使酶激活荷尔蒙和生长因子而调节鱼的生长发育;再次它能够分裂激肽源底物释放出激肽, 而激肽通过放松血管平滑肌, 增加血管紧张素, 提高血管通透因子的活性来调整血压, 同时激肽能够增强鱼类精子活力。所以激肽释放酶原Prokallikrein的发现为研究激肽释放酶kallikreins对鱼类健康和疾病的影响提供了新的研究思路。2 海洋蛋白酶解活性肽天然存在的海洋活性多肽由于在生物体中含量低, 而且提取困难, 难以实现大量生产供给所需, 化学人工合成多肽成本昂贵。所以, 人们更多地把目光投向开发蛋白酶解产物获得活性多肽这条途径上来。由于海洋生物生存的环境与陆地生物完全不同, 如高压、低温、高温和高盐等极端环境, 为了适应这些极端的海洋生物环境, 海洋生物蛋白质无论氨基酸的组成还是氨基酸的序列都与陆地生物蛋白有很大的不同, 同时, 海洋生物蛋白资源无论在种类和数量上都远远大于陆地蛋白资源, 并且未得到很好的开发。种类繁多的海洋蛋白氨基酸序列中, 潜在着许多具有生物活性的氨基酸序列, 用特异的蛋白酶水解, 就释放出有活性的肽段。海洋生物蛋白资源是21世纪人类重要的蛋白类食物及生物活性物质的重要来源。我国目前的海洋生物蛋白资源总量在世界各国名列前茅, 但我国目前的蛋白类水产品中, 除一部分直接食用外, 大部分通过简单的加工技术制成食品进入市场, 加工技术落后, 产品结构单一, 产品的附加值低, 使得产品在国际市场上的竞争力较差。因此, 我国急需对海洋生物蛋白资源进行优化利用和高值化加工。 1979年, Oshima [27] 等首次报道了利用细菌胶原酶水解凝胶并从其水解物中分离出6种降血压肽, 此后, 利用酶工程技术, 从其它食品蛋白质中分离的降血压肽相继出现, 这些肽在体外有抑制血管紧张素转化酶 (ACE) 的活性, 在体外有明显的降血压作用。近年来, 从海洋鱼类及其它水产品中发现的降压肽见表2 [28-30] 。在天然降血压肽的结构与功能的关系研究中, 一般认为若肽C末端是Pro, Phe, Tyr或序列中含有疏水氨基酸则有较高活性。对于二肽, 若N末端为甘氨酸残基时, 其对ACE的抑制作用可因C末端不同而相差300倍, C末端为Tyr, Trp, Pro则有较强的抑制作用。若C末端为甘氨酸残基时, 其对ACE的抑制作用可因N末端不同仅相差16倍, 其中N末端为Val, Ile, Arg是最有效的。最强的ACE抑制二肽Val-Trp比最弱的ACE抑制二肽Pro-Gly抑制作用高10 000倍。这说明ACE与底物或竞争性抑制剂的氨基酸残基结合有高度的专一性 [28] 。 2000年, Rozenn Ravallec-Plé等 [31] 利用商品酶Alcalase○R (Novo Nordisk, Nanterre, France) 对鳕鱼肉进行水解, 得到高品质的鱼蛋白水解物 (FPHs) , 水解产物中含有细胞生长因子、促分泌素 (胃泌素和缩胆囊素) 等。2001年, Rozenn Ravallec-Plé等 [32] 利用同一种酶Alcalase○R对加工沙丁鱼的废弃物进行水解, 得到了多种生物活性多肽:胃泌素、降钙素基因相关肽 (CGRP) 、细胞生长因子等。目前, 大多采用陆地酶工程技术应用于海洋蛋白酶解活性肽的研究, 如中性蛋白酶、碱性蛋白酶、胃蛋白酶、木瓜蛋白酶等。但是由于陆地生态环境与海洋生态环境有很大差异, 海洋蛋白的氨基酸序列和组成与陆地蛋白源也存在很大差别。所以, 陆地酶制剂可能无法高效用于海洋蛋白的酶解。因此, 应该从海洋生物体内、海水及海洋污泥中分离、纯化可高效酶解不同海洋蛋白的蛋白酶原。3 结语目前, 国内外研究和开发的活性多肽主要来源于陆生动植物, 如从牛乳提取的具有免疫调节功能的活性肽、来自大豆的多肽等, 而来源于海洋生物的活性肽非常少, 这决不意味着海洋生物活性肽资源缺乏, 而是长久以来没有进行很好的开发。人体所必须的全部氨基酸都可以在海洋生物中提取到, 而且含量极其丰富, 因此海洋生物体内的各种活性物质, 是开发研究海洋多肽药物与功能性保健食品的原料宝库。随着人们对海洋资源认识的提高, 以及现代生物技术在海洋药物研究中的应用, 使得人们对海洋活性肽的研究易于进行。相信在不久的将来, 海洋生物活性多肽的开发将为人类战胜疾病, 探索生命奥秘开辟新的道路。免责声明：本文为行业交流学习，版权归原作者所有，如有侵权，可联系删除。

微生物疗法

2024-03-12

·PRNewswire

Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.

"Company Prepares for Clinical Trials with Esteemed Addition: Dr. Mark T. Hamann, Endowed Chair of Drug Discovery and Biomedical Sciences at the MUSC College of Pharmacy" MELBOURNE, Fla., March 12, 2024 /PRNewswire/ -- Branded Legacy (OTC.PK: BLEG), Inc., a trailblazing BioTech holdings company, proudly announces the strategic acquisition of Sycamore BioPharma, Inc, a distinguished developer of plant-based pharmaceuticals. This strategic milestone not only fortifies Branded Legacy's standing as a prominent player in the biotech sector but also secures assets exceeding $2 million, along with key personnel crucial for advancing clinical trials following this successful union. Renowned for its meticulous development of wellness solutions, ranging from gummies to compression sleeves and pain-relieving topical creams, Sycamore BioPharma has earned acclaim as a prolific product developer. The acquisition brings forth over $500,000 in high-quality, ready-to-sell inventory and aligns seamlessly with Branded Legacy's dedication to quality, authenticity, and a commitment to natural ingredients. David Oswald, CEO at Branded Legacy, Inc., expresses enthusiasm about the acquisition, stating, "Branded Legacy is thrilled to embrace Sycamore BioPharma into our family of companies. This tactical move not only compliments our existing portfolio, but also brings us several steps closer to our goal of achieving FDA approval for several of our pharmaceutical products.." The acquisition not only opens new markets for Sycamore BioPharma but also provides access to Branded Legacy's extensive network, enhancing the company's ability to connect with consumers, build brand loyalty, and drive sales growth. It was also a crucial step in securing and maintaining a slew of large white label manufacturing and extraction contracts. Tyler Stone, President of Sycamore Biopharma, Inc., is also enthusiastic about the acquisition stating, "Branded Legacy brings significant strengths in areas where Sycamore BioPharma was seeing significant challenges. Their network and consumer outreach will undoubtedly drive sales growth of our innovative products and we are proud to be a part of the Branded Legacy network of companies." The collaboration between Branded Legacy and Sycamore BioPharma is poised to unlock synergies across various business facets. Leveraging Branded Legacy's web properties, brand management, and marketing expertise, the integration aims to maximize the reach and impact of Sycamore BioPharma's groundbreaking wellness solutions. Furthermore, the addition of Dr. Mark Hamann, a PHD holding scientist, to Branded Legacy's roster will enhance efforts in developing novel pharmaceuticals and streamline the FDA approval process, particularly in clinical trials. Dr. Mark T. Hamann, the newly appointed Director of Clinical Trials at Branded Legacy, brings a wealth of expertise as the Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery and Biomedical Sciences at the Medical University of South Carolina College of Pharmacy. Holding Adjunct appointments with The University of Maryland's Institute of Marine and Environmental Technology and the Bigelow Marine Laboratory in Maine, Dr. Hamann's distinguished career commenced in GMP pharmaceutical manufacturing at Solvay Pharmaceuticals in Baudette, Minnesota. Throughout his career, Dr. Hamann has authored over 250 scientific papers, reviews, and book chapters, while mentoring over 100 graduate students, postdoctoral fellows, and visiting scholars. Dr. Hamann's graduate studies led to the discovery of the anticancer agent, kahalalide F, which advanced to clinical trials in collaboration with biotech company PharmaMar. Currently serving as an Associate Editor for Biochimica et Biophysica Acta, General Subjects, Dr. Hamann's research group is actively engaged in the isolation, structure determination, and synthesis optimization of natural products and toxins. Their focus on plant and invertebrate microbiomes aligns with Branded Legacy's commitment to sustainable pharmaceutical development. Dr. Hamann's ongoing projects include the preclinical development of a small pipeline of natural products with potential applications against cancer, emerging infectious diseases, and neuropsychiatric disorders. His extensive experience and dedication to advancing scientific frontiers make him a valuable addition to Branded Legacy's mission to deliver high-quality, scientifically-backed solutions in the biotech industry. Branded Legacy has already begun supplying the Medical University of South Carolina with samples of mitragynine extract in order to build an effective experimental design for addiction mitigation. Although these trials are arduous, Branded Legacy is committed to doing whatever is necessary to support the process and offer these therapies to the patients who need them as quickly as possible In other company news, Branded Legacy has just completed a move to a significantly larger facility, accommodating the expanding operations and facilitating enhanced capabilities. The move comes in tandem with the acquisition of millions of dollars worth of state-of-the-art scientific and extraction equipment, solidifying Branded Legacy's commitment to staying at the forefront of innovation in the biotech industry. The new facility not only provides increased space for research and development but also positions Branded Legacy to meet the rising demand for its innovative wellness solutions. The acquisition of advanced scientific and extraction equipment further strengthens the company's technological infrastructure, supporting its endeavors in drug discovery, pharmaceutical development, and the optimization of natural products. For more information about Sycamore BioPharma, Inc, please visit: Original Copy of this Press Release: For media inquiries, please contact: Investor Relations & Media Contact Joe Holladay Branded Legacy Phone: 321-345-3565 Email: [email protected] Website: About Branded Legacy, Inc.: Branded Legacy, Inc. (OTC: BLEG) is a diversified holdings company focused on the biotech sector. With a commitment to excellence and innovation, Branded Legacy specializes in the development and marketing of cutting-edge products and services, including ventures in biotechnology, digital solutions, and wellness products. Safe Harbor Statement on Forward-Looking Language: This release includes forward-looking statements, subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The company disclaims any intention or obligation to update or revise forward-looking statements. Forward-looking statements may be identified by words such as "may," "will," "expect," "believe," "anticipate," "estimate," and similar expressions. SOURCE Branded Legacy Inc.

100 项与 Kahalalide F 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	荷兰	Vrije Universiteit Amsterdam	2004-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2004	临床1期	去势抵抗性前列腺癌	33	Kahalalide F	壓齋選鏇廠壓壓鏇鹹鏇(齋獵繭遞壓衊繭鑰獵齋) = Drug related toxicities were rapidly reversible CTC grade 3 and 4 AST and ALT that occurred at 560, 700 and 930 μg/m2/day and phlebitis and hypersensitivity reactions. 構繭蓋鑰餘簾蓋膚簾壓 (蓋憲製醖襯鏇鬱網網遞 ) 更多	-	2004-07-15